- Home
- BEAT vs ETHZW Comparison
BEAT vs ETHZW Comparison
Compare BEAT & ETHZW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- ETHZW
- Stock Information
- Founded
- BEAT 2015
- ETHZW N/A
- Country
- BEAT United States
- ETHZW United States
- Employees
- BEAT N/A
- ETHZW N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- ETHZW Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- ETHZW Health Care
- Exchange
- BEAT Nasdaq
- ETHZW Nasdaq
- Market Cap
- BEAT 37.7M
- ETHZW 35.3M
- IPO Year
- BEAT 2021
- ETHZW 2017
- Fundamental
- Price
- BEAT $1.33
- ETHZW $0.18
- Analyst Decision
- BEAT Buy
- ETHZW
- Analyst Count
- BEAT 1
- ETHZW 0
- Target Price
- BEAT $8.00
- ETHZW N/A
- AVG Volume (30 Days)
- BEAT 119.2K
- ETHZW N/A
- Earning Date
- BEAT 11-06-2025
- ETHZW N/A
- Dividend Yield
- BEAT N/A
- ETHZW N/A
- EPS Growth
- BEAT N/A
- ETHZW N/A
- EPS
- BEAT N/A
- ETHZW N/A
- Revenue
- BEAT N/A
- ETHZW N/A
- Revenue This Year
- BEAT N/A
- ETHZW N/A
- Revenue Next Year
- BEAT N/A
- ETHZW N/A
- P/E Ratio
- BEAT N/A
- ETHZW N/A
- Revenue Growth
- BEAT N/A
- ETHZW N/A
- 52 Week Low
- BEAT $0.91
- ETHZW N/A
- 52 Week High
- BEAT $3.48
- ETHZW N/A
- Technical
- Relative Strength Index (RSI)
- BEAT 56.41
- ETHZW N/A
- Support Level
- BEAT $1.27
- ETHZW N/A
- Resistance Level
- BEAT $1.54
- ETHZW N/A
- Average True Range (ATR)
- BEAT 0.10
- ETHZW 0.00
- MACD
- BEAT 0.02
- ETHZW 0.00
- Stochastic Oscillator
- BEAT 53.88
- ETHZW 0.00
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.